Based on our leading-edge platforms and profound knowledge of autoimmune diseases, researchers from Creative Biolabs have earned a great reputation from our clients for superior custom drug development services. We offer a full range of juvenile idiopathic arthritis (JIA) drug development services to support our global clients with R&D, preclinical, and clinical development programs.
JIA is a rare and complex autoinflammatory disease of childhood associated with significant morbidity. JIA often persists into adulthood and can result in significant long-term morbidity, including physical disability. JIA is characterized by arthritis accompanied by high spiking fevers, plus a variety of additional features such as a typical rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis.
Historically, the management of JIA has relied on nonsteroidal medications with the slow addition of traditional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate or sulfasalazine, and systemic corticosteroids. Patients with polyarticular and systemic JIA, however, often have disease refractory to traditional agents and/or face significant potential adverse effects.
With the advent of novel biologic therapeutics, there has been a rapid increase in the number of and types of agents available for the treatment of JIA. As a top-ranking provider in the drug development market, Creative Biolabs offers various platforms to deal with the urgent demands for autoimmune diseases such as JIA, including but not limited to:
Based on our years of experience and the most devoted scientists, Creative Biolabs has gained significant knowledge in JIA drug development. We are confident to deliver you the most suitable solution that can meet your specific requirements. Please feel free to contact us. We look forward to discussing your inquiry and finding the best solution for your needs.
For Research Use Only | Not For Clinical Use